Up‐ and down‐regulation of human lymphokine (IL‐2)‐activated killer cell induction by monocytes, depending on their functional state
- 15 January 1988
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 41 (1) , 33-40
- https://doi.org/10.1002/ijc.2910410108
Abstract
Studies were made to determine whether freshly isolated monocytes from healthy donors could influence the induction of lymphokine (IL‐2)‐activated killer (LAK) activity. Highly purified lymphocytes ( > 99%) and monocytes (>90%) were isolated by counter‐flaw centrifugal elutriation from peripheral blood. Lymphocytes incubated for 4 days with IL‐2 showed significant LAK activity against natural killer (NK) cell‐resistant target (Daudi) cells, whereas monocytes treated for 4 days with IL‐2 and/or IFN‐γ were not cytotoxic. Under the experimental conditions used, addition of monocytes to the lymphocyte cultures resulted in significant augmentation of the LAK activity, depending on the density of monocytes added. In contrast, monocytes stimulated by lipopolysaccha‐ride (LPS) markedly suppressed LAK activity induced by IL‐2, depending on the dose of LPS added. Similar up‐ and down‐regulations of LAK cell induction by monocytes were observed with 4 lines of human lung cancer cells as targets for LAK activity. Although supernatants from untreated monocytes did not increase LAK induction, supernatants from LPS‐stimulated monocytes suppressed LAK induction. The regulatory role of monocytes could not be replaced by the addition of exogenous interleukin I (IL‐1) or tumor necrosis factor (TNF). Prostaglandin E did not seem to play a regulatory role, since addition of indomethacin did not affect the regulation of LAK cell induction by monocytes‐ These results clearly indicate that human monocytes may cause up‐ or down‐regulation of the expression of IL‐2 induced LAK activity, depending on their functional state.This publication has 33 references indexed in Scilit:
- Role of alveolar macrophages in pulmonary neoplasiasBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells.The Journal of Experimental Medicine, 1985
- Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes.The Journal of Experimental Medicine, 1985
- Monocyte-mediated augmentation of human natural cell-mediated cytotoxicityCellular Immunology, 1985
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytesBiochemical and Biophysical Research Communications, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2International Journal of Cancer, 1981